Who is WATCHMAN For?


background image of man hiking

Consider WATCHMAN for your patients with
non-valvular AF, a high risk of stroke and:

  • Contraindication or intolerance to oral anticoagulants (OAC)1
  • High-risk of bleeding (HAS-BLED >3) or history of bleeding4
  • Prior stroke or TIA2
  • Suboptimal OAC treatment

Listen to the physician's perspective on the need for LAA closure therapy in patients with NVAF


WATCHMAN is the only device proven to safely and effectively reduce the risk of stroke and the long term risk of bleeding associated with OAC use in patients with non-valvular AF.

LAAC Guidelines & Recommendations:

  • 2016 ESC Guidelines for the management of atrial fibrillation
  • EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion

A Physician's Perspective


Stroke & Bleeding
Risk Assessment

1. For contraindications, refer to Instructions for use of anticoagulant drugs. NOACs (dabigatran, rivaroxaban, and apixaban) are not recommended in patients with severe renal impairment (CrCl <30 mL/min) - ESC guideline 2016.
2. Transient Ischemic Attack
3. Examples: difficulties to stabilize INR (International Normalized Ratio) in the therapeutic range, compliance issues, drug discontinuation.
4. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Camm AJ et al. European Heart Journal 2012;33:2719-2747. 

CAUTION: The law restricts these devices to sale by our on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the U.S., Japan and France.